Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23683510 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MAPK1LMNAHSD17B10GLA | |
| SCHEMBL18585913 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MAPK1LMNAHSD17B10GLA | |
| SCHEMBL18585909 | 0.89 | GAA (0.42) | ALDH1A1MAPK1LMNAHSD17B10GLA | |
| SCHEMBL18585911 | 0.89 | GAA (0.42) | ALDH1A1MAPK1LMNAHSD17B10GLA | |
| SCHEMBL5121118 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPK1BTKTSHRJAK3 | |
| SCHEMBL2251284 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPK1BTKTSHRJAK3 | |
| SCHEMBL18616042 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MAPK1BTKTSHRJAK3 | |
| SCHEMBL22138107 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL22138108 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL19230457 | 0.83 | ALDH1A1 (0.41) | ALDH1A1LMNABTKTSHRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745152-A2 | PEPTIDES BINDING TO BFL-1 | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-3341008-B1 | PEPTIDES BINDING TO BFL-1 | DANA FARBER CANCER INST INC (US) | 2026-04-15 | — | — | EP | claimed |
| US-20240294574-A1 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. | 2024-09-05 | — | — | US | claimed |
| US-11834520-B2 | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-12-05 | — | — | US | claimed |
| US-20220213146-A1 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. | 2022-07-07 | — | — | US | claimed |
| US-20220169688-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-02 | — | — | US | claimed |
| EP-3962933-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | Dana-Farber Cancer Institute, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| CN-114026113-A | Selective targeting of ubiquitin and ubiquitin-like E1 activating enzymes by structurally stabilized peptides | 丹娜法伯癌症研究院 | 2022-02-08 | — | — | CN | claimed |
| US-11078246-B2 | Peptides binding to Bfl-1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-08-03 | — | — | US | claimed |
| EP-3737404-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | claimed |
| US-20190002514-A1 | PEPTIDES BINDING TO BFL-1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | claimed |
| EP-3341008-A2 | PEPTIDES BINDING TO BFL-1 | Dana-Farber Cancer Institute, Inc. (US) | 2018-07-04 | — | — | EP | claimed |
| WO-2017040329-A2 | PEPTIDES BINDING TO BFL-1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-09 | — | — | WO | claimed |
| WO-2017040323-A2 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-03-09 | — | — | WO | claimed |
| US-8486722-B1 | Sensing method for biopolymers and sensing device therefor | NATIONAL UNIVERSITY CORPORATION TOYOHASHI UNIVERSITY OF TECHNOLOGY (JP) | 2013-07-16 | — | — | US | claimed |
| US-20130164862-A1 | SENSING METHOD FOR BIOPOLYMERS AND SENSING DEVICE THEREFOR | TANAKA SABURO (JP) | 2013-06-27 | — | — | US | claimed |
| US-8105493-B2 | Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit | JNC CORPORATION (JP) | 2012-01-31 | — | — | US | claimed |
| US-20090001025-A1 | AGGREGATION AND DISPERSION METHODS OF MAGNETIC PARTICLES, SEPARATION AND DETECTION METHODS USING THE SAME AND DETECTION KIT | CHISSO CORPORATION (JP) | 2009-01-01 | — | — | US | claimed |
| EP-2009442-A2 | Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit | Chisso Corporation (JP) | 2008-12-31 | — | — | EP | claimed |
| US-20070218567-A1 | SENSING METHOD FOR BIOPOLYMERS AND SENSING DEVICE THEREFOR | NATIONAL UNIV CORP TOYOHASHI UNIV OF TECHNOLOGY (JP) | 2007-09-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294574-A1 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | HSPBP1, HSPA8, PTMS | ALDH1A1 4618/4885MAPK1 3018/4885LMNA 3651/4885 |
| US-11834520-B2 | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides | MCL1, BCL2L1, BCL2L11 | ALDH1A1 4140/4885MAPK1 532/4885LMNA 2869/4885 |
| US-11078246-B2 | Peptides binding to Bfl-1 | BCL2L11, BCL2L1, BCL2L13 | ALDH1A1 4518/4885MAPK1 3317/4885LMNA 2697/4885 |
| US-20190002514-A1 | PEPTIDES BINDING TO BFL-1 | BCL2L11, BCL2L1, BCL2L13 | ALDH1A1 4518/4885MAPK1 3317/4885LMNA 2697/4885 |
| US-20220169688-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | UBE2E1, MDM2, UBA1 | ALDH1A1 1322/4885MAPK1 3234/4885LMNA 3415/4885 |
| US-20220213146-A1 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | HSPBP1, HSPA8, PTMS | ALDH1A1 4618/4885MAPK1 3018/4885LMNA 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.